 |
answer text |
<p>The Medicines and Healthcare products Regulatory Agency (MHRA) is taking urgent
action to deliver improvements to decision timescales in established medicines, including
those indicated to treat Parkinson’s disease. Last week we approved additional licences
for this critical area. Whilst no specific discussions have taken place between the
MHRA and my Rt hon. Friend, the Secretary of State for Health and Social Care on this
matter, we are taking significant steps to assess applications for medicine approval
within statutory timeframes and will always prioritise applications according to public
health need.</p><p>We are working to reduce timelines by bringing in additional resources
and developing processes that will result in significantly improved response times,
while protecting patient safety. The measures we are putting in place are already
resulting in significant improvements, and we will continue to publish monthly updates
providing applicants with transparent information on expected timescales. As an effective
regulator, we are committed to the highest of standards of performance and delivering
the right outcomes for patients and public health.</p>
|
|
